Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors. PanTher Therapeutics’ Sagitarri™ platform brings a novel spin to traditional oncology drugs, helping deliver active ingredients to the tumor without affecting the bloodstream leveraging interventional oncology procedures.
PanTher Therapeutics